TMSP(SH:600671) Zheng Quan Ri Bao·2025-05-16 16:39Core Viewpoint - ST Muyu Pharmaceutical Co., Ltd. is undergoing a strategic transformation following a change in control, with improved financial performance and operational efficiency expected in the coming years [2][3]. Group 1: Company Overview - ST Muyu is the first A-share listed company in Hangzhou and the first A-share listed company for traditional Chinese medicine preparations in China [2]. - The actual controller of the company has changed to the Qingdao Laoshan District Finance Bureau, which has led to a series of equity acquisitions and management changes [2]. Group 2: Financial Performance - In 2024, the company achieved a net profit attributable to shareholders of 15.25 million yuan, with a net profit of 9.96 million yuan after deducting non-recurring gains and losses [2]. - The company reported a significant increase in revenue for the first quarter of 2025, reaching 52.29 million yuan, representing a year-on-year growth of 88.55% [3]. - The net profit for the first quarter of 2025 was 5.09 million yuan, marking a turnaround from previous losses [3]. Group 3: Management and Strategy - A professional management team with rich industry experience has been established under the new state-owned control, which is expected to enhance decision-making and market positioning [3]. - The company is focusing on core businesses such as traditional Chinese medicine, raw materials, and health products, while also optimizing operational strategies to reduce costs and increase efficiency [3]. - The completion of internal control defect rectification has been confirmed, with a standard unqualified opinion issued by the accounting firm on the internal control audit report [3].